Literature DB >> 2003631

Capacity of US labs to provide TLI in support of early HIV-1 intervention.

R O Valdiserri1, G D Cross, A R Gerber, R E Schwartz, T L Hearn.   

Abstract

We surveyed laboratories to assess their capacity to perform T-lymphocyte immunophenotyping. Of the 1026 respondents, 279 located in 41 states and the District of Columbia performed this type of testing. Most laboratories were located in hospitals, reported a low weekly test volume, and indicated that it took 6-24 weeks for flow cytometer operators to become proficient. Many laboratories appear to have the capacity to perform additional CD4+ cell testing, but training additional operators may be necessary. The paucity of laboratories performing T-lymphocyte immunophenotyping in the public sector may affect referral patterns from that setting.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2003631      PMCID: PMC1405034          DOI: 10.2105/ajph.81.4.491

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  8 in total

Review 1.  Issues for quality assurance in clinical flow cytometry.

Authors:  R C McCarthy; T J Fetterhoff
Journal:  Arch Pathol Lab Med       Date:  1989-06       Impact factor: 5.534

2.  Targeting AIDS prevention and treatment toward HIV-1-infected persons. The concept of early intervention.

Authors:  D P Francis; R E Anderson; M E Gorman; M Fenstersheib; N S Padian; K W Kizer; M A Conant
Journal:  JAMA       Date:  1989-11-10       Impact factor: 56.272

3.  Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS.

Authors:  W Lang; H Perkins; R E Anderson; R Royce; N Jewell; W Winkelstein
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

4.  Centers for Disease Control perspective on quality assurance for human immunodeficiency virus type 1 antibody testing. Model Performance Evaluation Program.

Authors:  R O Valdiserri; R N Taylor; T L Hearn; W O Schalla; H W Muir
Journal:  Arch Pathol Lab Med       Date:  1990-03       Impact factor: 5.534

5.  Serum beta 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis.

Authors:  B Hofmann; Y X Wang; W G Cumberland; R Detels; M Bozorgmehri; J L Fahey
Journal:  AIDS       Date:  1990-03       Impact factor: 4.177

6.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

7.  The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group.

Authors:  J Phair; A Muñoz; R Detels; R Kaslow; C Rinaldo; A Saah
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

8.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.